Published in final edited form as:

J Neurosci Methods. 2015 August 30; 252: 55–63. doi:10.1016/j.jneumeth.2015.02.002.

Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of Attention Deficit Hyperactivity Disorder

Sucharita S. Somkuwar¹, Kathleen M. Kantak², and Linda P. Dwoskin¹

¹Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536, USA

²Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts 02215, USA

Abstract

Attention Deficit Hyperactivity Disorder (ADHD) is associated with hypofunctional medial prefrontal cortex (mPFC) and orbitofrontal cortex (OFC). Methylphenidate (MPH) remediates ADHD, in part, by inhibiting the norepinephrine transporter (NET). MPH also reduces ADHD-like symptoms in Spontaneously Hypertensive Rats (SHRs), a model of ADHD. However, effects of chronic MPH treatment on NET function in mPFC and OFC in SHR have not been reported. In the current study, long-term effects of repeated treatment with a therapeutically relevant oral dose of MPH during adolescence on NET function in subregions of mPFC (cingulate gyrus, prelimbic cortex and infralimbic cortex) and in the OFC of adult SHR, Wistar-Kyoto (WKY, inbred control) and Wistar (WIS, outbred control) rats were determined using in vivo voltammetry. Following local ejection of norepinephrine (NE), uptake rate was determined as peak amplitude (A_{max}) x first-order rate constant (k_{-1}). In mPFC subregions, no strain or treatment effects were found in NE uptake rate. In OFC, NE uptake rate in vehicle-treated adult SHR was greater than in adult WKY and WIS administered vehicle. MPH treatment during adolescence normalized NE uptake rate in OFC in SHR. Thus, the current study implicates increased NET function in OFC as an underlying mechanism for reduced noradrenergic transmission in OFC, and consequently, the behavioral deficits associated with ADHD. MPH treatment during adolescence normalized NET function in OFC in adulthood, suggesting that the therapeutic action of MPH persists long after treatment cessation and may contribute to lasting reductions in deficits associated with ADHD.

Corresponding Author: Linda P. Dwoskin, Address: 789 South Limestone, 465 Biological Pharmaceutical Complex, Lexington, KY 40536-0596, ldwoskin@email.uky.edu.

Conflict of interest

The authors have no financial interests or conflicts of interest to disclose.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

Norepinephrine transporter; in vivo voltammetry; Spontaneously Hypertensive Rat; Attention Deficit/Hyperactivity Disorder; orbitofrontal cortex

1 Introduction

Attention deficit hyperactivity disorder (ADHD) is one of the most prevalent neurobehavioral disorders, affecting ~12–15% of children worldwide and persisting into adulthood in ~4–5% of individuals (Froehlich et al., 2007; Polanczyk et al., 2007). ADHD etiology, although multigenetic (Faraone et al., 2005; Gizer et al., 2009; Kuntsi and Klein, 2012), has been associated with polymorphisms of the norepinephrine transporter (NET) gene (Barr et al., 2002; Kollins et al., 2008; McEvoy et al., 2002). However, altered noradrenergic function in ADHD has not been verified in clinical studies (Zimmer, 2009), in part, due to the paucity of suitable radioligands probing NET for use in positron emission tomography studies (Ding et al., 2006). Importantly, compelling evidence supporting the involvement of the noradrenergic system in ADHD pathology comes from the common mechanism of action of all of the currently available FDA-approved therapeutics for ADHD. ADHD medications increase noradrenergic neurotransmission either via inhibition of NET function (e.g., methylphenidate; MPH, amphetamine and atomoxetine) or by activation of post-synaptic α 2A adrenergic receptors (e.g., guanfacine) (Berridge et al., 2006; Bymaster et al., 2002; Fernando et al., 2012; Ma et al., 2005). Thus, ADHD pathology is strongly connected to deficits in noradrenergic neurotransmission and the efficacy of ADHD therapeutics is associated with increased noradrenergic transmission (Levy, 2009).

The prefrontal cortex has been associated with the hallmark symptoms of ADHD and has been linked to the beneficial effects of ADHD therapeutics in preclinical models (Arnsten, 2009; Berridge and Devilbiss, 2011). For example, administration of a therapeutically relevant low dose of MPH (2.0 mg/kg, i.p.) in rats produced positive blood oxygen dependent signals in the orbitofrontal cortex (OFC), a subregion of prefrontal cortex (Easton et al., 2009; Kuczenski and Segal, 2002). Inhibition of α 2 adrenergic receptors by local administration of yohimbine into the dorsolateral prefrontal cortex of primates resulted in impaired spatial working memory, increased impulsivity and increased locomotor hyperactivity, thus resulting in behaviors consistent with an ADHD profile (Li and Mei, 1994; Ma et al., 2005; Ma et al., 2003) and suggesting a role for noradrenergic neurotransmission in prefrontal cortex in ADHD pathology.

Effects of NET inhibition by ADHD therapeutics on prefrontal cortex function have been elaborated also using preclinical models. MPH is an equipotent inhibitor of NET and dopamine transporter (DAT), with K_i values for inhibition of [3 H]dopamine and [3 H]norepinephrine (NE) uptake of 160 nM and 40 nM, respectively (Easton et al., 2007b; Richelson and Pfenning, 1984). At therapeutically relevant doses (0.5 - 2 mg/kg, i.p.), MPH inhibits NET function and preferentially increases extracellular NE in prefrontal cortex compared to subcortical areas, as well as compared to dopamine in prefrontal cortex (Berridge et al., 2006). Increasing extracellular NE activates α 2A receptors and decreases the concentrations of the intracellular second messenger, cyclic adenosine monophosphate

(cAMP), thereby enhancing the strength and duration of firing of pyramidal neurons in prefrontal cortex (Wang et al., 2007). Enhanced pyramidal neuronal firing is hypothesized to be the mechanism by which ADHD medications improve attention and working memory and reduce impulsivity (Sagvolden, 2006; Wang et al., 2007). MPH indirectly increases the activation of cortical α 2A adrenergic receptors in non-human primates and rats (Arnsten, 2009; Gamo et al., 2010). Thus, enhancing noradrenergic neurotransmission in the prefrontal cortex via inhibition of NET function is critical for the therapeutic action of MPH. However, few studies have investigated the long-term consequences of MPH treatment during adolescence on NET function during adulthood.

The Spontaneously Hypertensive Rat (SHR) is a well-established model of ADHD that exhibits several of the behavioral and neurochemical features of ADHD (de Villiers et al., 1995; Oades et al., 2005; Russell et al., 1995; Sagvolden, 2011; Sagvolden et al., 2005). In SHR, noradrenergic systems in the locus coeruleus and hypothalamus are inadequately regulated by α 2A autoreceptors and heterologous glutamatergic receptors, resulting in enhanced NE release (de Villiers et al., 1995; Howells and Russell, 2008; Russell et al., 2005). Importantly, α 2A auto-receptor mediated regulation of NE release is decreased in prefrontal cortical slices from SHR (Russell et al., 2000). Notably, alterations in NET function in the prefrontal cortex of SHR have not been reported.

Previous studies in SHR found that MPH treatment during adolescence produces lasting changes in DAT function in prefrontal cortex as well as in its subregion, the medial prefrontal cortex (mPFC; Harvey et al., 2011; Somkuwar et al., 2013). Specifically, DAT function was increased in mPFC of MPH-treated SHR compared to vehicle-treated SHR as well as compared to MPH-treated Wistar Kyoto rats (WKY, inbred control) and Wistar rats (WIS, outbred control). The aim of the current study was to evaluate *in vivo* NET function in subregions of prefrontal cortex, including the cingulate gyrus (CG), prelimbic cortex (PrL), infralimbic cortex (IL) and lateral orbitofrontal cortex (LO). We chose to separately target the CG, PrL and the IL cortex subregions of mPFC, because these regions have distinct intracortical and subcortical connections (Heidbreder and Groenewegen, 2003; Hoover and Vertes, 2007; Vertes, 2006). Specifically, the CG and the dorsal PrL are thought to project to motor and sensory cortices, while the ventral PrL and IL project to limbic and associative areas. As such, these individual subregions may differentially influence ADHD pathology (Easton et al., 2007a). Also, the current study describes a novel method for isolating NET function in prefrontal cortex using an *in vivo* voltammetry approach. Differences were revealed between SHR and the WKY and WIS controls following administration of MPH or vehicle throughout adolescence on NET function during adulthood.

2 Materials and Methods

2.1 Drugs and Reagents

($\pm$)-MPH was purchased from Sigma-Aldrich Corporation (St. Louis, MO). MPH was dissolved in water to obtain a concentration of 1.5 mg/ml (prepared daily) and injected into oyster crackers (Kantak et al., 2008) to attain a dose of 1.5 mg/kg for oral administration. ($\pm$)-Norepinephrine (+)-bitartrate (NE), GBR12909 (1-2-[bis(4-fluorophenyl)methoxy]ethyl)-4-(3-phenylpropyl)piperazine dihydrochloride), ascorbic acid,

perchloric acid (70%), sodium chloride and Nafion perfluorinated ion-exchange resin (5% solution) were purchased from Sigma-Aldrich Corporation (St. Louis, MO). Sodium phosphate dibasic and monobasic were purchased from Fischer Scientific (Fair Lawn, NJ). Urethane and sticky wax were purchased from Sigma Life-Sciences (St. Louis, MO) and FDJ/On time LLC (Winter Park, FL), respectively.

2.2 Animals

For optimization of the NE clearance assay, male and female adult Sprague-Dawley rats were obtained from the Harlan Laboratories Inc. (Indianapolis, IN). Some of the rats used for optimization experiments were drug and experimentally naïve and others experienced operant or Pavlovian conditioning, including acute treatment with morphine (10 mg/kg or 45 mg/kg, i.p.). Consequently, rats that underwent conditioning experienced greater handling and enrichment compared to the experimentally naïve rats. Although optimization experiments to identify the effect of DAT inhibition on NE clearance in PFC were conducted 1–2 weeks after treatment, large variability in the data may have been a consequence of the variation in treatment history.

For experiments investigating the effect of MPH treatment during adolescence, naïve male SHR, WKY and WIS rats were obtained at postnatal day (P) 25 from Charles River Laboratories/US facilities (Kingston, NY or Raleigh, NC). Vendor location is a critical to ensure homogeneity with respect to ADHD (SHR) and non-ADHD (WKY and WIS) phenotypes. WKY from Charles River/GER have been characterized as a model for the predominantly inattentive subtype of ADHD (Sagvolden et al., 2009), and have a large number of discordant SNP genotypes (35%) relative to WKY from Charles River/US and Harlan/UK, which have only 2.5% discordant SNP genotypes (Zhang-James et al., 2013). Further, WKY from Harlan/UK is a well-recognized control for the SHR ADHD phenotype (Sagvolden et al., 2009), supporting the use of WKY from Charles River/US as the inbred control for the current studies.

All rats were individually housed with free access to food and water (unless specified otherwise) in a colony room maintained on a 12-hour light:dark cycle (lights on 07:00 h) in the DLAR (University of Kentucky, Lexington, KY). All experimental and rat handling procedures were approved by the Institutional Animal Care and Use Committee at the University of Kentucky and were performed in accordance with the 1996 version of the *National Institutes of Health Guide for the Care and Use of Laboratory Animals*.

2.3 Treatment

Following three days of habituation, SHR, WKY and WIS rats were administered MPH (1.5 mg/kg, p.o.) or vehicle (VEH, water, 1 ml/kg, p.o.) from P28 to P55, the time period from early to late adolescence (Doremus-Fitzwater et al., 2010; Spear, 2000). MPH was administered orally to mimic the route of administration employed in patients with ADHD. MPH or vehicle was administered daily Monday through Friday to mimic the weekend medication holiday often practiced in the treatment of children and adolescents with ADHD (American Psychiatric Association., 2013). The dose of MPH (1.5 mg/kg, p.o.) in outbred rats provides clinically relevant plasma concentrations of MPH (Wargin et al., 1983) that

increase extracellular NE and dopamine in prefrontal cortex, but are below threshold for producing locomotor activation or for increasing dopamine concentrations in striatum (Berridge et al., 2006; Kuczenski and Segal, 2002). In adolescent SHR, MPH (1.5 mg/kg, p.o.) improves attention and behavioral flexibility when administered from P28-P55 (Harvey et al., 2013; Harvey et al., 2011).

From P56 onwards, rats were housed individually with free access to food and water in a colony room until the electrochemical experiments were conducted. Between P77-91 rats were anesthetized with urethane (1.5 g/kg, i.p.) and placed in a stereotaxic frame (David Kopf Instruments, Tujunga, CA). Urethane was chosen because it does not alter DAT function *in vivo* (Sabeti et al., 2003). Body temperature was maintained at 34–35°C (rat core temperature; DeBow and Colbourne, 2003) using a heating pad coupled with a rectal thermometer (Harvard Apparatus, Holliston, MA). A longitudinal incision was made in the scalp and the skin was retracted. Bleeding was stopped by local application of epinephrine (5 µg/ml, in saline) and a styptic-powder with benzocaine (Kwikstop, ARC Laboratories, Atlanta, GA). Excess epinephrine was washed away and the exposed skull was air-dried. A small hole was drilled into the skull over the posterior cortex for placement of an Ag/AgCl silver reference electrode. A larger hole was drilled into the skull overlying the mPFC and LO, and the dura was removed to expose the cortex. The exposed cortex was cleaned of blood using sterile saline. The electrode-micropipette assembly was lowered into the CG (+2.9mm AP, ± 0.8 mm ML, -1.6 mm DV), PrL (dorsal +2.9 mm AP, ± 0.8 mm ML, -2.5 mm DV and ventral +2.9 mm AP, ± 0.8 mm ML, -3.2 mm DV), IL (+2.9 mm AP, ± 0.8 mm ML, -4.2 mm DV) and LO (+3.2 mm AP, ± 2.6 mm ML, -4.2 mm DV). Typically, recordings from the mPFC subregions and from the LO were conducted in the contralateral hemispheres (randomized between experiments) using a single electrode-micropipette assembly for recording from all the sites. However, if the assembly failed during any portion of the experiments (e.g., due to technical issues such as pipette clogging, loss in electrode sensitivity, etc.), a fresh calibrated electrode-micropipette assembly was used. In such cases, electrochemical recordings were conducted subsequently from the opposite hemisphere to avoid the subregion that may have been damaged by the previous electrode-micropipette assembly.

2.4 *In vivo* electrochemical measurements

High speed chronoamperometry is an electrochemical method for detecting molecules that readily undergo oxidation and reduction when in contact with an electrode held at an appropriate voltage; concentration of the molecule is directly proportional to the oxidation and reduction currents (Borland and Michael, 2007). NE and dopamine are electroactive analytes in which the catechol ring readily oxidizes to an orthoquinone and then reduces back to the catechol ring when a 0 V to 0.55 V square-wave pulse is applied in a physiological (pH 7.4) buffer. Specific DAT function has been inferred from real-time clearance of exogenously applied dopamine, thereby circumventing the potential confound of endogenous dopamine released from presynaptic terminals altering clearance parameter measurements (McCrae et al., 2005). DAT and NET share functional and structural homologies and have comparable substrate selectivity (Miller et al., 2010; Moron et al., 2002; Whiteside et al., 2005). Hence, the electrochemical procedures for NET function

employed in the current study were derived from methods from previous studies evaluating DAT function (Liu et al., 2009; Zhu et al., 2007). To assess NET function, NE clearance from the extracellular space was determined following local ejection of NE into Cg, PrL, IL and LO in urethane anesthetized rats based on published methods for evaluation of dopamine clearance (Zhu et al., 2007) with a few modifications. Briefly, the electrochemical recording electrodes (Center for Microelectrode Technology, Lexington, KY) consisted of a single carbon fiber (30 μm diameter) sealed in a glass capillary with 150 to 200 μm of the fiber length exposed. To enhance electrode selectivity for positively-charged catecholamines over negatively-charged endogenous analytes (e.g., ascorbic acid), the exposed region of the carbon-fiber electrode was coated with Nafion (10 swirls) and cured by heating at 200 $^{\circ}\text{C}$ for 5 min (Gerhardt et al., 1984). Electrodes were calibrated *in vitro* in 0.1 M phosphate buffer saline (pH 7.4) at room temperature and showed a linear current by concentration response for NE (2–8 μM) with correlation coefficients ranging from 0.98 to 1.00. A Fast16 mkIII system (Fast Analytical Sensing Technology, Quanten, LLC, Nicholasville, KY) was used for electrode calibration and subsequent *in vivo* experiments. Selectivity for NE over ascorbic acid ranged from 30 - 6800 to 1, which results in an acceptable 3.1% variation (range 96.7 – 99.8%) between the most and the least accurate NE signals. Electrode selectivity depends on environmental temperature and humidity during the Nafion coating process. The process was repeated until selectivity for NE over ascorbic acid reached >30:1. The limit of detection for the electrodes ranged from 0.01 – 0.51 μM (average = 0.11 μM). Each electrode was attached to a single-barrel micropipette (internal tip diameter, 10 – 20 μm) with sticky-wax such that the electrode and the micropipette were 100–400 μm apart.

For optimization experiments determining NET function in the absence and presence of GBR12909, the micropipette, immediately prior to lowering the recording assembly into the region of interest, was filled with a non-saturating NE solution (200 μM) with ascorbic acid (100 μM) in saline (0.9% sodium chloride; Hospira Inc, IL) at pH 7.2–7.4. The selected concentration of NE (200 μM) was based on prior studies evaluating dopamine clearance in the mPFC using *in vivo* voltammetry (Zhu et al., 2007). Although, NET expression is greater than DAT in prefrontal cortex, NE has a high affinity for DAT, and thus, NE may be nonspecifically cleared by DAT (Moron et al., 2002). Clearance of NE by DAT was inhibited by including the specific DAT inhibitor GBR12909 (Andersen, 1989) to isolate NET function. GBR12909 (50 nM) was used at a concentration ~15-fold higher than the K_i for inhibition of dopamine uptake at DAT (Matecka et al., 1997). Effects of DAT inhibition on NE clearance in mPFC subregions and in LO were evaluated using a within-subject design ($n = 3\text{--}4/\text{group}$). Brain regions of interest in one hemisphere received NE solution (200 μM) containing GBR12909 (50 nM) and the other hemisphere received NE solution in the absence of GBR12909, with conditions randomized between experiments. At 5 min intervals, the NE solution in the absence or presence of GBR12909 was pressure-ejected (20–25 psi) from the micropipette using a Picospritzer II (General Valve Corporation, Fairfield, NJ). The volume ejected (~264 nl/mm) was measured using a reticule with a millimeter scale fitted in the eyepiece of a stereomicroscope (Leica Microsystems Inc., Buffalo Grove, IL) that was focused on the meniscus of the solution in the micropipette. Oxidation potential (+0.55 V for 100 msec) and reduction potential (0 V for 100 msec) were applied alternately to produce a square-wave potential. Electrochemical measurements of

oxidation and reduction currents were made at 5 Hz and averaged to 1 Hz using the Fast16 mkIII system. Stable baseline was defined as 3 consecutive signals for which the maximal amplitudes did not differ by $\pm 10\%$ following a constant ejection volume of NE solution. For each experiment, 3 to 5 stable signals were recorded.

For experiments in SHR and control strains determining the effect of MPH treatment during adolescence on NET function in adulthood ($n = 6-9/\text{group}$), a single-barrel micropipette containing NE solution (100 μM) with GBR 12909 (50 nM) and ascorbic acid (100 μM) in saline (pH 7.2–7.4) was attached to the Nafion-coated carbon-fiber electrode and lowered into the CG or LO. MPH treatment during adolescence was found previously to increase DAT function in mPFC of adult SHR (Somkuwar et al., 2013). Thus, to ensure that MPH treatment-dependent changes in DAT function did not interfere with MPH-induced alterations in NET function, GBR 12909 was retained in the NE solution in these experiments. NE clearance was recorded from the four brain regions of interest using a within-subject design. Sequence of recording from mPFC and LO was randomized. Order of recording for CG, PrL and IL subregions of mPFC was sequential as the depth of the electrode placement increased. That is, following 3 to 5 stable signals from one mPFC subregion, the electrode-pipette assembly was moved ventral to the next mPFC subregion.

2.5 Verification of electrode placement

Immediately after each recording session, brains were removed and flash-frozen using 2-methylbutane and stored at -80°C for histological evaluation of microelectrode recording tracks. Brains were sectioned along the coronal plane (20 μm sections) using a Leica 1850 M cryostat (Nussloch, Germany), and sections were thaw mounted onto Fisher SuperFrost Plus® slides. Slides were stored overnight at room temperature under desiccation and stained with cresyl violet for determination of electrode placement. Probe placements (tissue displacement) were evaluated under a light microscope (1 X magnification; Fig 4.1). Position of the tip of the electrode was estimated visually by referencing histological landmarks including corpus collosum, anterior commissure and rhinal fissure while referring to the rat brain atlas (Paxinos, 1991). Only data from histologically confirmed microelectrode placements were included in the subsequent analyses of results.

2.6 Electrochemical data acquisition and statistical analysis

Data were processed using a customized Matlab®-based analysis package, FastAnalysis Version 5.0 (Jason Burmeister Consulting, LLC). The primary parameters for evaluating NE clearance were peak amplitude (A_{max} , in μM) and first-order rate constant (k_{-1} , in sec^{-1}) of the NE signal (Liu et al., 2009). Amount of NE applied was adjusted to ensure that the A_{max} ranged from 0.6 to 1.5 μM and was comparable between subjects. Range of A_{max} was selected a priori based on previous studies evaluating DA clearance by DAT in striatum (Hebert and Gerhardt, 1999) to ensure that extracellular NE concentrations were not saturating. Data for three stable measurements of A_{max} and k_{-1} were averaged for each brain region for each rat. First order uptake rate was calculated as the product of peak amplitude and first order rate constant ($A_{\text{max}} \times k_{-1}$, in nM/sec; Stephens et al., 2011).

Statistical analyses were conducted using SPSS Statistics Version 19 (SPSS Inc., IBM Company, Armonk, NY). Data are reported as mean $\pm$ S.E.M. and n represents the number of rats per group. For the optimization experiments, the dependent variables were compared using paired t-tests. For the MPH treatment experiments, dependent variables were compared using two-factor ANOVA (strain X treatment), followed by Bonferroni's post-hoc comparisons. Outliers were identified using the Grubbs test (GraphPad; <http://www.graphpad.com/quickcalcs/Grubbs1.cfm>) and were omitted from the analyses.

3 Results

3.1 Histological assessment of electrode placements in mPFC and OFC

Electrode tip placements in mPFC and OFC are illustrated in Fig 1. For LO, electrode placement was between +3.2 to +4.0 mm anterior and 2.4 to 2.7 mm lateral to bregma. For IL, electrode placement was between +2.7 to +3.2 mm anterior and 0.5 and 1.0 mm lateral to bregma. One WKY rat in the MPH treatment experiment was excluded from the mPFC analyses due to electrode placement outside the acceptable range of co-ordinates.

3.2 NE clearance via NET in the absence and presence of GBR12909 inhibition of DAT

No differences were found in the amount of NE ejected (Supplementary Table S1) or $A_{\max}$ (Table 1) when NE was applied in the absence and presence of GBR12909 (50 nM). The average volume of solution that was pressure ejected was 28.6 ± 2.14 nL. For the CG, dorsal PrL, ventral PrL, IL and LO subregions, no differences were found in the first order uptake rate of NE in the absence and presence of GBR12909 (Table 2).

3.3 Effects of methylphenidate treatment during adolescence on NET function in adulthood

No differences were found in the amount of NE applied (Supplementary Table S2) and in the $A_{\max}$ (Table 3) between MPH- and VEH-treated SHR, WKY and WIS in CG, dorsal PrL, ventral PrL, IL and LO subregions. The average volume of solution that was pressure ejected into the brain regions was 47.8 ± 4.61 nL.

For first order uptake rate of NE in the LO, a significant strain X treatment interaction was found ($F[2,45] = 4.38$, $p < 0.05$; Fig 2). Post-hoc comparisons revealed that the uptake rate in VEH-treated SHR was greater than the uptake rate in VEH-treated WKY and WIS. Importantly, MPH treatment during adolescence reduced the first order uptake rate in adult SHR. No treatment differences were found between the VEH- and MPH-treated WKY and WIS control strains. Further, the uptake rate in MPH-treated SHR was not different from the uptake rate in VEH- and MPH-treated WKY and WIS. In contrast, no differences were found between MPH- and VEH-treated SHR, WKY and WIS in the first order uptake rate of NE in CG, dorsal PrL, ventral PrL and IL (Table 4).

4 Discussion

The current study used an *in vivo* voltammetric method to study NET function in the prefrontal cortex in an animal model of ADHD. The results revealed that NE uptake rate in the LO subregion of OFC was greater in vehicle-treated SHR than in vehicle-treated WKY

and WIS. Importantly, MPH treatment during adolescence followed by cessation of treatment during adulthood decreased the NE uptake rate in LO of SHR, such that uptake rate in MPH-treated SHR was not different from vehicle- and MPH-treated WKY and WIS rats. No effects of strain or treatment were found in subregions of mPFC (including CG, dorsal and ventral PrL, and IL), revealing regional specificity of the effect. The observed increase in NE uptake rate reflects increased NET function, suggesting that adult SHR have reduced extracellular NE and reduced noradrenergic transmission in OFC. Importantly, adolescent treatment with MPH normalized this deficit in noradrenergic transmission detected in adult SHR, and this effect of MPH persisted into adulthood. Thus, MPH treatment during adolescence resulted in long-lasting mitigation of the aberrant noradrenergic transmission in SHR rats with an ADHD phenotype.

The *in vivo* voltammetric method used to evaluate NE clearance within prefrontal cortex was adapted from previously published methods for determining DA clearance within the prefrontal cortex (Zhu et al., 2007). Results revealed that inhibition of DAT function by GBR12909 in mPFC and OFC subregions did not alter first order uptake rate of NE, suggesting that DAT does not contribute significantly to NE clearance in these regions. With respect to the results from the optimization experiments, a large between-subjects variation in uptake rate (Table 2) was observed, despite the within-subject design and the low variation in A_{max} (Table 1). This was likely due to the small number of subjects and the variation in treatment history of the subjects. Nevertheless, the overall lack of effect of DAT inhibition by GBR12909 on PFC NET function reported herein is consistent with findings from previous report (Moron et al., 2002). Specifically, GBR12909 did not inhibit dopamine uptake into frontal cortical synaptosomes from mice, indicating that NET is responsible predominantly for dopamine uptake in the prefrontal cortex, and the contribution of DAT was minimal (Moron et al., 2002). However, previous studies revealed that MPH treatment during adolescence increased DAT function in the mPFC of adult SHR compared to vehicle control as well as compared to MPH-treated WKY and WIS (Somkuwar et al., 2013). Thus, to avert the possibility that enhanced DAT function in SHR contributes to alterations in NE clearance in prefrontal cortex, the use of GBR12909 was continued in subsequent experiments.

One potential limitation of the measure of first order uptake rate is that it does not take into account the amount of substrate (in this study, NE) applied via micropipette; amount of substrate applied alters A_{max} (Zhu et al., 2007). As a consequence, the amount of NE applied may complicate the interpretation of NET function using uptake rate. Clearance is another measure of transporter function that does account for the amount of substrate applied (Zhu et al., 2013; Zhu et al., 2007). In the current study, there were no significant between-group differences in the amount of NE applied (see Supplementary Table S2), and the range of A_{max} (0.6–1.5 μM) was selected *a priori* based on previous work. Moreover, for studies that control A_{max} between experimental groups, uptake rate has been justified as an indicator of transporter function (Littrell et al., 2012; Miller et al., 2012). Thus, NE uptake rate was considered an appropriate indicator of NET function for the current study.

Increased NET function in the LO subregion of the OFC in the SHR is indicative of a hypofunctional noradrenergic system in this brain region, which may underlie behavioral

deficits observed in the SHR, such as impaired reversal learning, strategy set-shifting and working memory (Harvey et al., 2013; Kantak et al., 2008; Sagvolden, 2006). Further, reduced noradrenergic function in the OFC has been reported to contribute to disruption of goal-directed actions and to increased impulsive behavior (Schwabe et al., 2012; Sun et al., 2010). Reduced noradrenergic function in the OFC may contribute also to ADHD-related behavioral deficits via reduced modulation of noradrenergic and dopaminergic neuronal firing in the locus coeruleus and ventral tegmental area, respectively (Aston-Jones and Cohen, 2005; Chandler et al., 2013). Taken together, the current study contributes to our understanding by identifying an increase in NET function specifically in OFC as a potential neurochemical mechanism for the behavioral deficits in ADHD.

MPH exerts its therapeutic effects, at least in part, by inhibiting NET function and increasing extracellular NE concentrations in prefrontal cortex (Arnsten and Li, 2005; Berridge et al., 2006; Richelson and Pfenning, 1984; Wang et al., 2007). Increased extracellular NE induced by therapeutically relevant doses of MPH activates $\alpha 2A$ receptors on cortical pyramidal neurons, and thereby, improves prefrontal cortical-mediated functions including attention and impulsivity (Arnsten and Li, 2005; Bari et al., 2011; Wang et al., 2007). The current results indicate that chronic MPH treatment during adolescence normalizes the elevated NET function in OFC of SHR that persists long after treatment discontinuation.

Of note, MPH treatment during adolescence did not result in persistent alterations in NET function in any prefrontal cortex sub-regions evaluated in control WKY and WIS rats. Previous research has shown that NET expression and function in the forebrain increases from birth to PND 15, but NET expression is steady in adulthood (Coyle and Axelrod, 1971; Sanders et al., 2005). Furthermore, $\alpha 2$ -adrenergic receptors in rat cortex follow a similar developmental trajectory (Happe et al., 2004). Thus, the noradrenergic system in prefrontal cortex is developmentally vulnerable during the juvenile period and is relatively stable during adolescence. Therefore, pharmacological manipulation, such as treatment with a low dose of MPH during adolescence, is not expected to produce lasting adaptations to the noradrenergic system in prefrontal cortex in control subjects.

In individuals with ADHD, cortical maturation is delayed during development (Castellanos and Proal, 2012; Posner et al., 2011). As a consequence, the noradrenergic system in the ADHD population may be more susceptible to adaptations following treatment with MPH during adolescence. Furthermore, MPH treatment is often discontinued because several ADHD symptoms diminish with age (Faraone et al., 2006; McCarthy et al., 2009). The current study revealed that MPH treatment during adolescence normalized NET function in an animal model of ADHD. Thus, by extrapolation, MPH treatment in adolescents with ADHD may contribute to the age-related reduction in ADHD symptoms, such that the functional improvement persists long after treatment discontinuation.

The therapeutic benefits of MPH treatment during adolescence may be offset by the long-term consequences on drug abuse risk. Adult SHR exhibit increased cocaine self-administration compared to WKY and WIS (Harvey et al., 2011; Somkuwar et al., 2013). MPH treatment in adolescent SHR followed by treatment discontinuation further increased

cocaine self-administration during adulthood (Harvey et al., 2011) and was associated with increased DAT function in mPFC, but not in OFC (Somkuwar et al., 2013). Similarly, non-medicated adults with ADHD are more vulnerable to drug abuse, including cocaine, compared to individuals without ADHD, which has been attributed to neurobehavioral deficits of ADHD such as enhanced ventral striatal hypo-responsiveness during reward anticipation and enhanced impulsivity (Biederman et al., 1998; Lee et al., 2011; Schres et al., 2007). The later in childhood that MPH treatment is initiated, the greater the risk of drug abuse during adulthood, but this association may be moderated by conduct problems in children with ADHD (Dalsgaard et al., 2014; Mannuzza et al., 2008). Consequences of initiation of MPH treatment in a purely adolescent ADHD population have not yet been determined.

5 Conclusion

In conclusion, the current study reveals that NET function is increased in the OFC of SHR and that chronic MPH treatment during adolescence normalized NET function that persisted into adulthood. Elevated NET function in the OFC may contribute to behavioral deficits in SHR. The action of MPH for decreasing NET function may underlie the normalization of ADHD-related behavioral deficits in SHR. Extrapolating these results to individuals with ADHD, increased NET function in the OFC may contribute to the ADHD phenotype, and MPH treatment during adolescence may normalize OFC NET function and result in improvements in ADHD symptoms that may persist long after treatment discontinuation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This study was funded by grant R01 DA11716, P50 DA05312, UL1 TR000117 and a Kentucky Opportunity Fellowship. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Drug Abuse. Experiments adhered to the Institutional Animal Care and Use Committee guidelines for animal research.

References

- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5. American Psychiatric Association; Washington, DC: 2013.
- Andersen PH. The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action. *Eur J Pharmacol.* 1989; 166:493–504. [PubMed: 2530094]
- Arnsten AF. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: An important role for prefrontal cortex dysfunction. *CNS Drugs.* 2009; 23 (Suppl 1):33–41. [PubMed: 19621976]
- Arnsten AF, Li BM. Neurobiology of executive functions: Catecholamine influences on prefrontal cortical functions. *Biological Psychiatry.* 2005; 57:1377–84. [PubMed: 15950011]
- Aston-Jones G, Cohen JD. Adaptive gain and the role of the locus coeruleus-norepinephrine system in optimal performance. *J Comp Neurol.* 2005; 493:99–110. [PubMed: 16254995]
- Bari A, Mar AC, Theobald DE, Elands SA, Oganya KC, Eagle DM, Robbins TW. Prefrontal and monoaminergic contributions to stop-signal task performance in rats. *J Neurosci.* 2011; 31:9254–63. [PubMed: 21697375]

- Barr CL, Kroft J, Feng Y, Wigg K, Roberts W, Malone M, Ickowicz A, Schachar R, Tannock R, Kennedy JL. The norepinephrine transporter gene and attention-deficit hyperactivity disorder. *Am J Med Genet.* 2002; 114:255–9. [PubMed: 11920844]
- Berridge CW, Devilbiss DM. Psychostimulants as cognitive enhancers: The prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder. *Biological Psychiatry.* 2011; 69:e101–11. [PubMed: 20875636]
- Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B, Hamilton C, Spencer RC. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. *Biological Psychiatry.* 2006; 60:1111–20. [PubMed: 16806100]
- Biederman J, Wilens TE, Mick E, Faraone SV, Spencer T. Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? *Biological Psychiatry.* 1998; 44:269–73. [PubMed: 9715358]
- Borland, LM.; Michael, AC. An Introduction to Electrochemical Methods in Neuroscience. In: Michael, AC.; Borland, LM., editors. *Electrochemical Methods for Neuroscience*. Boca Raton (FL): 2007.
- Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. *Neuropsychopharmacology.* 2002; 27:699–711. [PubMed: 12431845]
- Castellanos FX, Proal E. Large-scale brain systems in ADHD: Beyond the prefrontal-striatal model. *Trends in Cognitive Sciences.* 2012; 16:17–26. [PubMed: 22169776]
- Chandler DJ, Lamperski CS, Waterhouse BD. Identification and distribution of projections from monoaminergic and cholinergic nuclei to functionally differentiated subregions of prefrontal cortex. *Brain Research.* 2013; 1522:38–58. [PubMed: 23665053]
- Coyle JT, Axelrod J. Development of the uptake and storage of L-(³H)norepinephrine in the rat brain. *J Neurochem.* 1971; 18:2061–75. [PubMed: 5129345]
- Dalsgaard S, Mortensen PB, Frydenberg M, Thomsen PH. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood - a naturalistic long-term follow-up study. *Addictive Behaviors.* 2014; 39:325–8. [PubMed: 24090624]
- de Villiers AS, Russell VA, Sagvolden T, Searson A, Jaffer A, Taljaard JJ. Alpha 2-adrenoceptor mediated inhibition of [³H]dopamine release from nucleus accumbens slices and monoamine levels in a rat model for attention-deficit hyperactivity disorder. *Neurochem Res.* 1995; 20:427–33. [PubMed: 7651580]
- DeBow S, Colbourne F. Brain temperature measurement and regulation in awake and freely moving rodents. *Methods.* 2003; 30:167–71. [PubMed: 12725783]
- Ding YS, Lin KS, Logan J. PET imaging of norepinephrine transporters. *Current Pharmaceutical Design.* 2006; 12:3831–45. [PubMed: 17073682]
- Doremus-Fitzwater TL, Varlinskaya EI, Spear LP. Motivational systems in adolescence: Possible implications for age differences in substance abuse and other risk-taking behaviors. *Brain Cogn.* 2010; 72:114–23. [PubMed: 19762139]
- Easton N, Marshall F, Fone KC, Marsden CA. Differential effects of the D- and L- isomers of amphetamine on pharmacological MRI BOLD contrast in the rat. *Psychopharmacology.* 2007a; 193:11–30. [PubMed: 17387459]
- Easton N, Marshall FH, Marsden CA, Fone KC. Mapping the central effects of methylphenidate in the rat using pharmacological MRI BOLD contrast. *Neuropharmacology.* 2009; 57:653–64. [PubMed: 19733553]
- Easton N, Steward C, Marshall F, Fone K, Marsden C. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. *Neuropharmacology.* 2007b; 52:405–14. [PubMed: 17020775]
- Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: A meta-analysis of follow-up studies. *Psychol Med.* 2006; 36:159–65. [PubMed: 16420712]

- Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, Sklar P. Molecular genetics of attention-deficit/hyperactivity disorder. *Biological Psychiatry*. 2005; 57:1313–23. [PubMed: 15950004]
- Fernando AB, Economidou D, Theobald DE, Zou MF, Newman AH, Spoelder M, Caprioli D, Moreno M, Hipolito L, Aspinall AT, Robbins TW, Dalley JW. Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonists. *Psychopharmacology*. 2012; 219:341–52. [PubMed: 21761147]
- Frøehlich TE, Lanphear BP, Epstein JN, Barbaresi WJ, Katusic SK, Kahn RS. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. *Arch Pediatr Adolesc Med*. 2007; 161:857–64. [PubMed: 17768285]
- Gamo NJ, Wang M, Arnsten AF. Methylphenidate and atomoxetine enhance prefrontal function through alpha2-adrenergic and dopamine D1 receptors. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2010; 49:1011–23. [PubMed: 20855046]
- Gerhardt GA, Oke AF, Nagy G, Moghaddam B, Adams RN. Nafion-coated electrodes with high selectivity for CNS electrochemistry. *Brain Research*. 1984; 290:390–5. [PubMed: 6692152]
- Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: A meta-analytic review. *Human Genetics*. 2009; 126:51–90. [PubMed: 19506906]
- Häppe HK, Coulter CL, Gerety ME, Sanders JD, O'Rourke M, Bylund DB, Murrin LC. Alpha-2 adrenergic receptor development in rat CNS: An autoradiographic study. *Neuroscience*. 2004; 123:167–78. [PubMed: 14667451]
- Harvey RC, Jordan CJ, Tassin DH, Moody KR, Dwoskin LP, Kantak KM. Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: Methylphenidate vs. atomoxetine treatments. *Behav Brain Res*. 2013; 244:38–47. [PubMed: 23376704]
- Harvey RC, Sen S, Deaciuc A, Dwoskin LP, Kantak KM. Methylphenidate treatment in adolescent rats with an attention deficit/hyperactivity disorder phenotype: Cocaine addiction vulnerability and dopamine transporter function. *Neuropsychopharmacology*. 2011; 36:837–47. [PubMed: 21150910]
- Hebert MA, Gerhardt GA. Age-related changes in the capacity, rate, and modulation of dopamine uptake within the striatum and nucleus accumbens of Fischer 344 rats: An in vivo electrochemical study. *J Pharmacol Exp Ther*. 1999; 288:879–87. [PubMed: 9918602]
- Heidbreder CA, Groenewegen HJ. The medial prefrontal cortex in the rat: Evidence for a dorso-ventral distinction based upon functional and anatomical characteristics. *Neurosci Biobehav Rev*. 2003; 27:555–79. [PubMed: 14599436]
- Hoover WB, Vertes RP. Anatomical analysis of afferent projections to the medial prefrontal cortex in the rat. *Brain Structure & Function*. 2007; 212:149–79. [PubMed: 17717690]
- Howells FM, Russell VA. Glutamate-stimulated release of norepinephrine in hippocampal slices of animal models of attention-deficit/hyperactivity disorder (spontaneously hypertensive rat) and depression/anxiety-like behaviours (Wistar-Kyoto rat). *Brain Research*. 2008; 1200:107–15. [PubMed: 18295191]
- Kantak KM, Singh T, Kerstetter KA, Dembro KA, Mutebi MM, Harvey RC, Deschepper CF, Dwoskin LP. Advancing the spontaneous hypertensive rat model of attention deficit/hyperactivity disorder. *Behav Neurosci*. 2008; 122:340–57. [PubMed: 18410173]
- Kollins SH, Anastopoulos AD, Lachiewicz AM, FitzGerald D, Morrissey-Kane E, Garrett ME, Keatts SL, Ashley-Koch AE. SNPs in dopamine D2 receptor gene (DRD2) and norepinephrine transporter gene (NET) are associated with continuous performance task (CPT) phenotypes in ADHD children and their families. *Am J Med Genet B Neuropsychiatr Genet*. 2008; 147B:1580–8. [PubMed: 18821566]
- Kuczenski R, Segal DS. Exposure of adolescent rats to oral methylphenidate: Preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. *The Journal of Neuroscience*. 2002; 22:7264–71. [PubMed: 12177221]
- Kuntsi J, Klein C. Intraindividual variability in ADHD and its implications for research of causal links. *Current Topics in Behavioral Neurosciences*. 2012; 9:67–91. [PubMed: 21769722]

- Lee SS, Humphreys KL, Flory K, Liu R, Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: A meta-analytic review. *Clinical Psychology Review*. 2011; 31:328–41. [PubMed: 21382538]
- Levy F. Dopamine vs noradrenaline: Inverted-U effects and ADHD theories. *The Australian and New Zealand Journal of Psychiatry*. 2009; 43:101–8. [PubMed: 19153917]
- Li BM, Mei ZT. Delayed-response deficit induced by local injection of the alpha 2-adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys. *Behav Neural Biol*. 1994; 62:134–9. [PubMed: 7993303]
- Littrell OM, Pomerleau F, Huettl P, Surgener S, McGinty JF, Middaugh LD, Granholm AC, Gerhardt GA, Boger HA. Enhanced dopamine transporter activity in middle-aged Gdnf heterozygous mice. *Neurobiology of Aging*. 2012; 33:427 e1–14. [PubMed: 21144620]
- Liu YP, Lin YL, Chuang CH, Kao YC, Chang ST, Tung CS. Alpha adrenergic modulation on effects of norepinephrine transporter inhibitor reboxetine in five-choice serial reaction time task. *J Biomed Sci*. 2009;16. [PubMed: 19272183]
- Ma CL, Arnsten AF, Li BM. Locomotor hyperactivity induced by blockade of prefrontal cortical alpha2-adrenoceptors in monkeys. *Biological Psychiatry*. 2005; 57:192–5. [PubMed: 15652880]
- Ma CL, Qi XL, Peng JY, Li BM. Selective deficit in no-go performance induced by blockade of prefrontal cortical alpha 2-adrenoceptors in monkeys. *Neuroreport*. 2003; 14:1013–6. [PubMed: 12802193]
- Mannuzza S, Klein RG, Truong NL, Moulton JL 3rd, Roizen ER, Howell KH, Castellanos FX. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: Prospective follow-up into adulthood. *The American Journal of Psychiatry*. 2008; 165:604–9. [PubMed: 18381904]
- Matecka D, Lewis D, Rothman RB, Dersch CM, Wojnicki FH, Glowa JR, DeVries AC, Pert A, Rice KC. Heteroaromatic analogs of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as high-affinity dopamine reuptake inhibitors. *J Med Chem*. 1997; 40:705–16. [PubMed: 9057857]
- McCarthy S, Asherson P, Coghill D, Hollis C, Murray M, Potts L, Sayal K, de Soysa R, Taylor E, Williams T, Wong IC. Attention-deficit hyperactivity disorder: Treatment discontinuation in adolescents and young adults. *Br J Psychiatry*. 2009; 194:273–7. [PubMed: 19252159]
- McCrae RR, Löckenhoff CE, Costa PT. A step toward DSM-V cataloguing personality-related problems in living. *European Journal of Personality* Volume 19, Issue 4. *European Journal of Personality*. 2005; 19:269–86.
- McEvoy B, Hawi Z, Fitzgerald M, Gill M. No evidence of linkage or association between the norepinephrine transporter (NET) gene polymorphisms and ADHD in the Irish population. *Am J Med Genet*. 2002; 114:665–6. [PubMed: 12210284]
- Miller DJ, Derefinko KJ, Lynam DR, Milich R, Fillmore MT. Impulsivity and attention deficit-hyperactivity disorder: Subtype classification using the UPPS impulsive behavior scale. *J Psychopathol Behav*. 2010; 32:323–32.
- Miller EM, Pomerleau F, Huettl P, Russell VA, Gerhardt GA, Glaser PE. The spontaneously hypertensive and Wistar Kyoto rat models of ADHD exhibit sub-regional differences in dopamine release and uptake in the striatum and nucleus accumbens. *Neuropharmacology*. 2012; 63:1327–34. [PubMed: 22960443]
- Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: Evidence from knockout mouse lines. *The Journal of Neuroscience*. 2002; 22:389–95. [PubMed: 11784783]
- Oades RD, Sadile AG, Sagvolden T, Viggiano D, Zuddas A, Devoto P, Aase H, Johansen EB, Ruocco LA, Russell VA. The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles. *Dev Sci*. 2005; 8:122–31. [PubMed: 15720370]
- Paxinos, G. *Atlas of the developing rat brain*. Academic Press; San Diego: 1991.
- Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. *Am J Psychiatry*. 2007; 164:942–8. [PubMed: 17541055]

- Posner J, Nagel BJ, Maia TV, Mechling A, Oh M, Wang Z, Peterson BS. Abnormal amygdalar activation and connectivity in adolescents with attention-deficit/hyperactivity disorder. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2011; 50:828–37. e3. [PubMed: 21784302]
- Richelson E, Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: Most antidepressants selectively block norepinephrine uptake. *Eur J Pharmacol*. 1984; 104:277–86. [PubMed: 6499924]
- Russell V, Allie S, Wiggins T. Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder--the spontaneously hypertensive rat. *Behavioural Brain Research*. 2000; 117:69–74. [PubMed: 11099759]
- Russell V, de Villiers A, Sagvolden T, Lamm M, Taljaard J. Altered dopaminergic function in the prefrontal cortex, nucleus accumbens and caudate-putamen of an animal model of attention-deficit hyperactivity disorder--the spontaneously hypertensive rat. *Brain Research*. 1995; 676:343–51. [PubMed: 7614004]
- Russell VA, Sagvolden T, Johansen EB. Animal models of attention-deficit hyperactivity disorder. *Behav Brain Funct*. 2005; 1:9. [PubMed: 16022733]
- Sabeti J, Gerhardt GA, Zahniser NR. Chloral hydrate and ethanol, but not urethane, alter the clearance of exogenous dopamine recorded by chronoamperometry in striatum of unrestrained rats. *Neuroscience Letters*. 2003; 343:9–12. [PubMed: 12749985]
- Sagvolden T. The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD). *Behav Brain Funct*. 2006; 2:41. [PubMed: 17173664]
- Sagvolden T. Impulsiveness, overactivity, and poorer sustained attention improve by chronic treatment with low doses of l-amphetamine in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD). *Behav Brain Funct*. 2011; 7:6. [PubMed: 21450079]
- Sagvolden T, Russell VA, Aase H, Johansen EB, Farshbaf M. Rodent models of attention-deficit/hyperactivity disorder. *Biological Psychiatry*. 2005; 57:1239–47. [PubMed: 15949994]
- Sagvolden T, Johansen EB, Wøien G, Walaas SI, Storm-Mathisen J, Bergersen LH, Hvalby O, Jensen V, Aase H, Russell VA, Killeen PR, Dasbanerjee T, Middleton FA, Faraone SV. The spontaneously hypertensive rat model of ADHD--the importance of selecting the appropriate reference strain. *Neuropharmacology*. 2009; 57:619–26. [PubMed: 19698722]
- Sanders JD, Happe HK, Bylund DB, Murrin LC. Development of the norepinephrine transporter in the rat CNS. *Neuroscience*. 2005; 130:107–17. [PubMed: 15561429]
- Scheres A, Milham MP, Knutson B, Castellanos FX. Ventral striatal hypo-responsiveness during reward anticipation in attention-deficit/hyperactivity disorder. *Biological Psychiatry*. 2007; 61:720–4. [PubMed: 16950228]
- Schwabe L, Tegenthoff M, Hoffken O, Wolf OT. Simultaneous glucocorticoid and noradrenergic activity disrupts the neural basis of goal-directed action in the human brain. *The Journal of Neuroscience*. 2012; 32:10146–55. [PubMed: 22836250]
- Somkuwar SS, Darna M, Kantak KM, Dwoskin LP. Adolescence methylphenidate treatment in a rodent model of attention deficit/hyperactivity disorder: Dopamine transporter function and cellular distribution in adulthood. *Biochem Pharmacol*. 2013; 86:309–16. [PubMed: 23623751]
- Spear L. Modeling adolescent development and alcohol use in animals. *Alcohol Res Health*. 2000; 24:115–23. [PubMed: 11199278]
- Stephens ML, Quintero JE, Pomerleau F, Huettl P, Gerhardt GA. Age-related changes in glutamate release in the CA3 and dentate gyrus of the rat hippocampus. *Neurobiology of Aging*. 2011; 32:811–20. [PubMed: 19535175]
- Sun H, Green TA, Theobald DE, Birnbaum SG, Graham DL, Zeeb FD, Nestler EJ, Winstanley CA. Yohimbine increases impulsivity through activation of cAMP response element binding in the orbitofrontal cortex. *Biological Psychiatry*. 2010; 67:649–56. [PubMed: 20163788]
- Vertes RP. Interactions among the medial prefrontal cortex, hippocampus and midline thalamus in emotional and cognitive processing in the rat. *Neuroscience*. 2006; 142:1–20. [PubMed: 16887277]

- Wang M, Ramos BP, Paspalas CD, Shu Y, Simen A, Duque A, Vijayraghavan S, Brennan A, Dudley A, Nou E, Mazer JA, McCormick DA, Arnsten AF. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. *Cell*. 2007; 129:397–410. [PubMed: 17448997]
- Wargin W, Patrick K, Kilts C, Gualtieri CT, Ellington K, Mueller RA, Kraemer G, Breese GR. Pharmacokinetics of methylphenidate in man, rat and monkey. *The Journal of Pharmacology and Experimental Therapeutics*. 1983; 226:382–6. [PubMed: 6410043]
- Whiteside SP, Lynam DR, Miller JD, Reynolds SK. Validation of the UPPS impulsive behaviour scale: A four-factor model of impulsivity. *European Journal of Personality*. 2005; 19:559–74.
- Zhang-James Y1, Middleton FA, Faraone SV. Genetic architecture of Wistar-Kyoto rat and spontaneously hypertensive rat substrains from different sources. *Physiological Genomics*. 2013; 45:528–38. [PubMed: 23673728]
- Zhu J, Bardo MT, Dwoskin LP. Distinct effects of enriched environment on dopamine clearance in nucleus accumbens shell and core following systemic nicotine administration. *Synapse*. 2013; 67:57–67. [PubMed: 23065942]
- Zhu J, Bardo MT, Green TA, Wedlund PJ, Dwoskin LP. Nicotine increases dopamine clearance in medial prefrontal cortex in rats raised in an enriched environment. *J Neurochem*. 2007; 103:2575–88. [PubMed: 17953677]
- Zimmer L. Positron emission tomography neuroimaging for a better understanding of the biology of ADHD. *Neuropharmacology*. 2009; 57:601–7. [PubMed: 19682469]

Highlights

- Methylphenidate (MPH) reduces ADHD by inhibiting norepinephrine transporter (NET)
- Long-term effects of MPH on NET function in orbitofrontal cortex (OFC) are unknown
- NET function was greater in OFC of a rat model of ADHD compared to non-ADHD control
- MPH during adolescence normalized NET function in ADHD model during adulthood
- Thus, some of the therapeutic action of MPH persists long after treatment cessation

Fig 1.

Neuroanatomical localization of electrodes. The regions of interest for evaluating NET function were lateral orbitofrontal cortex (LO; Top panel), the cingulate gyrus (CG), dorsal and ventral prelimbic cortex (PrL), and infralimbic cortex (IL; Bottom panel). Placements of the carbon-fiber electrode tips in the rodent LO (Top panel) and IL (Bottom panel) are shown for experiments determining the effect of dopamine transporter (DAT) inhibition (x marks) as well as for the experiments evaluating the effect of adolescent treatment with MPH (black dots).

Fig 2.

First order uptake rate of norepinephrine (NE) in the lateral orbitofrontal cortex (LO) of adult Spontaneously Hypertensive Rat (SHR), Wistar-Kyoto (WKY) and Wistar (WIS) rats treated with methylphenidate (MPH) or vehicle (VEH) during adolescence. NE (100 μ M; with GBR 12909, 50 nM) was applied locally to LO of each rat. First order uptake rate (in nM/sec) was mean $\pm$ S.E.M. product of the maximum amplitude (A_{max}) of the NE signal and the first order fitting of the signal decay (k_1). $n = 8-9$ /group; * $p < 0.05$ compared to the respective VEH control; # $p < 0.05$ compared to VEH-treated WKY and WIS.

Table 1
Maximum amplitude ($A_{\max}$) of the NE signal in the absence and presence of GBR12909 in subregions of mPFC and OFC in Sprague-Dawley rats

Maximum amplitude ($A_{\max}$) of the NE signal in mPFC, including cingulate gyrus (CG), dorsal and ventral prelimbic cortex (PrL), and infralimbic cortex (IL), and in the lateral orbitofrontal cortex (LO) in the absence and presence of GBR12909. NE (200 μ M) was applied alone (NE alone) or with GBR 12909 (50 nM; NE plus GBR12909) in opposite brain hemispheres for each rat. n = 3–4.

	Amax (μM)	
	NE alone	NE + GBR
CG	0.67 $\pm$ 0.09 ^a	0.79 $\pm$ 0.17
Dorsal PrL	1.1 $\pm$ 0.04	0.80 $\pm$ 0.04
Ventral PrL	1.0 $\pm$ 0.25	0.83 $\pm$ 0.11
IL	0.80 $\pm$ 0.21	0.99 $\pm$ 0.10
LO	1.3 $\pm$ 0.28	1.7 $\pm$ 0.30

^aValues are mean $\pm$ S.E.M.

Table 2
First order uptake rate of NE ($A_{\max} \times k_{-1}$) in the absence and presence of GBR12909 in subregions of mPFC and OFC in Sprague-Dawley rats

Uptake rate of NE (200 μ M) applied locally to subregions of mPFC, including cingulate gyrus (CG), dorsal and ventral prelimbic cortex (PrL), and infralimbic cortex (IL), and to the lateral orbitofrontal cortex (LO). NE was applied alone or in the presence of GBR 12909 (50 nM; NE plus GBR12909) in opposite brain hemispheres for each rat. n = 3–4.

	First order uptake rate (nM/sec)	
	NE alone	NE plus GBR12909
CG	0.11 $\pm$ 0.05 ^a	0.18 $\pm$ 0.10
Dorsal PrL	0.32 $\pm$ 0.04	0.21 $\pm$ 0.08
Ventral PrL	0.18 $\pm$ 0.01	0.20 $\pm$ 0.07
IL	0.15 $\pm$ 0.09	0.40 $\pm$ 0.18
LO	0.72 $\pm$ 0.27	0.75 $\pm$ 0.20

^aValues are mean $\pm$ S.E.M.

Table 3

Effect of MPH treatment during adolescence on maximum amplitude ($A_{\max}$) of the NE signal in mPFC and OFC of adult SHR, WKY and WIS rats

Maximum amplitude ($A_{\max}$) of the NE signal for subregions of mPFC, including cingulate gyrus (CG), dorsal and ventral prelimbic cortex (PrL), and infralimbic cortex (IL) and for lateral orbitofrontal cortex (LO) of adult Spontaneously Hypertensive Rat (SHR), Wistar-Kyoto (WKY) and Wistar (WIS) rats that were treated with methylphenidate (MPH) or vehicle (VEH) during adolescence. NE (100 μ M, with GBR 12909, 50 nM) was applied locally to each brain region using a within-subject design. $n = 7-9$ /group for CG, dorsal and ventral PrL and LO; $n = 6-8$ /group for IL.

	A _{max} (μM)				
	CG	Dorsal PrL	Ventral PrL	IL	LO
SHR-VEH	0.57 ± 0.11 ^a	0.68 ± 0.13	0.69 ± 0.13	0.67 ± 0.09	0.89 ± 0.15
SHR-MPH	0.74 ± 0.13	0.57 ± 0.07	0.68 ± 0.10	0.83 ± 0.17	0.87 ± 0.16
WKY-VEH	1.2 ± 0.33	0.81 ± 0.23	0.97 ± 0.37	0.65 ± 0.12	0.69 ± 0.15
WKY-MPH	0.67 ± 0.12	0.81 ± 1.4	0.86 ± 0.13	0.72 ± 0.11	0.62 ± 0.11
WIS-VEH	1.2 ± 0.28	1.2 ± 0.23	1.3 ± 0.25	1.2 ± 0.38	0.61 ± 0.09
WIS-MPH	1.5 ± 0.52	0.96 ± 0.25	0.73 ± 0.12	0.71 ± 0.07	0.95 ± 0.24
Statistics ^b	F[2,45]=0.41	F[2,44]=0.37	F[2,47]=0.31	F[2,41]=2.2	F[2,45]=0.94

^a Values are mean $\pm$ S.E.M.;

^b $p > 0.05$

Table 4
Effect of MPH treatment during adolescence on first order uptake rate of NE in mPFC during adulthood in SHR, WKY and WIS rats

First order uptake rate ($A_{\max} \times k_{-1}$) of NE and strain X treatment (3×2) ANOVA for mPFC subregions, including cingulate gyrus (CG), dorsal and ventral prelimbic cortex (PrL) and infralimbic cortex (IL), of adult Spontaneously Hypertensive Rat (SHR), Wistar-Kyoto (WKY) and Wistar (WIS) rats that were treated with methylphenidate (MPH) or vehicle (VEH) during adolescence. NE (100 μ M, with GBR 12909, 50 nM) was applied to each brain region using a within-subject design. n = 7–9/group for CG, dorsal and ventral PrL; n = 6–8/group for IL.

	First order uptake rate (nM/sec)			
	CG	Dorsal PrL	Ventral PrL	IL
SHR-VEH	0.29 ± 0.10	0.43 ± 0.15	0.34 ± 0.10	0.71 ± 0.19
SHR-MPH	0.44 ± 0.15	0.33 ± 0.11	0.48 ± 0.13	0.54 ± 0.13
WKY-VEH	0.50 ± 0.16	0.30 ± 0.06	0.34 ± 0.08	0.34 ± 0.12
WKY-MPH	0.38 ± 0.12	0.35 ± 0.12	0.47 ± 0.11	0.43 ± 0.08
WIS-VEH	0.63 ± 0.15	0.53 ± 0.12	0.56 ± 0.12	0.61 ± 0.19
WIS-MPH	0.71 ± 0.25	0.56 ± 0.30	0.33 ± 0.16	0.19 ± 0.05
Statistics^b	F[2,45]=0.39	F[2,44]=0.66	F[2,47]=1.5	F[2,41]=1.5

^aValues are mean ± S.E.M.;

^b
p > 0.05